Tretinoin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Tretinoin
- Tretinoin: From Undocumented Original Indication to Rheumatoid Nodulosis (Low-Confidence Signal)
Tretinoin: From Undocumented Original Indication to Rheumatoid Nodulosis (Low-Confidence Signal)
One-Sentence Summary
This evidence pack does not record tretinoin’s original approved indication or mechanism of action (both flagged as data gaps). The TxGNN model’s top-ranked prediction for this drug is Rheumatoid Nodulosis, but this signal is currently supported by 0 clinical trials and 0 publications — it is a model score with no corroborating evidence, and the drug’s known retinoid-related adverse effects (arthralgia/musculoskeletal symptoms) point in the opposite direction of the hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (data gap — DrugBank/SAHPRA licence data not yet retrieved) |
| Predicted New Indication | Rheumatoid Nodulosis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the structured original_moa field (data gap DG002). However, the pack’s own rationale text for other candidates confirms tretinoin is all-trans retinoic acid (ATRA), a RAR/RXR nuclear receptor ligand — a well-characterised class independent of this gap.
For the top-ranked prediction, the evidence pack itself argues against biological plausibility rather than for it: there is no direct mechanistic pathway linking retinoic acid signalling to rheumatoid nodule formation, and retinoid-class drugs are already known to cause arthralgia and musculoskeletal adverse effects — the opposite of a therapeutic effect on a joint/nodule-related condition. The pack’s own annotation concludes the high TxGNN score likely reflects a spurious association from “cartilage/joint” node proximity in the knowledge graph rather than a genuine drug–disease relationship.
Because no clinical trial or literature evidence exists for this specific pairing, there is no basis to support the prediction beyond the raw model score.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
No SAHPRA registrations are recorded for tretinoin in this evidence pack (total_licenses: 0, market status: Not marketed). Registration and Essential Medicines List status cannot be assessed until this data gap (DG001, blocking) is resolved via SAHPRA licence lookup.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(Key warnings, contraindications, and drug interaction data are all marked as data gaps in this pack — none could be verified.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked prediction (Rheumatoid Nodulosis) has zero clinical trials, zero literature, and a mechanistic rationale that actively contradicts the hypothesis. This does not meet even a minimal bar to advance past model-score-only status (L5/S0).
Note on other candidates in this batch: Two lower-ranked predictions in this pack have at least some literature support and were staged further (S1, “Research Question”): Osteoarthritis (rank 7, 20 PubMed records, though directionally mixed — some show retinoic acid as disease-modifying, others show it as OA-inducing) and Quinquaud’s folliculitis decalvans (rank 10, 1 case report on a related but non-identical condition). If prioritising within this drug’s candidate set, these two warrant review ahead of rheumatoid nodulosis.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI) — resolve blocking data gap DG001
- Confirmed mechanism of action from DrugBank — resolve high-severity gap DG002
- Confirmed original approved indication(s) for tretinoin
- If pursuing the OA or folliculitis decalvans signals instead: mechanistic studies resolving the conflicting direction of retinoic acid’s effect on cartilage/joint tissue
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.